Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

MLA

Craig, Timothy J., et al. “Efficacy and Safety of Garadacimab, a Factor XIIa Inhibitor for Hereditary Angioedema Prevention (VANGUARD): A Global, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial.” Lancet, vol. 401, no. 10382, Apr. 2023, pp. 1079–90. EBSCOhost, https://doi.org/10.1016/S0140-6736(23)00350-1.

APA

Craig, T. J., Reshef, A., Li, H. H., Jacobs, J. S., Bernstein, J. A., Farkas, H., Yang, W. H., Stroes, E. S. G., Ohsawa, I., Tachdjian, R., Manning, M. E., Lumry, W. R., Saguer, I. M., Aygören-Pürsün, E., Ritchie, B., Sussman, G. L., Anderson, J., Kawahata, K., Suzuki, Y., & Staubach, P. (2023). Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, 401(10382), 1079–1090. https://doi.org/10.1016/S0140-6736(23)00350-1

Chicago

Craig, Timothy J, Avner Reshef, H Henry Li, Joshua S Jacobs, Jonathan A Bernstein, Henriette Farkas, William H Yang, et al. 2023. “Efficacy and Safety of Garadacimab, a Factor XIIa Inhibitor for Hereditary Angioedema Prevention (VANGUARD): A Global, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial.” Lancet 401 (10382): 1079–90. doi:10.1016/S0140-6736(23)00350-1.